page full analyst note oct
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research oct
estim aug
price data oct
rate updat oct
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
develop pharmaceut platform
address comprehens sourc distribut need
manufactur provid employe
electron inventori platform compani equip ship
million product day world-wide global scale
sheer pharmaceut volum enabl compani
negoti competit price effici provid access
vast portfolio drug core busi roughli
revenu focus pharmaceut distribut
balanc revenu attribut acquir busi
handl roughli third drug sold
unit state creat extens footprint
physician-administ product key anchor custom
within commun compani oper effici
highli regul environ provid insul
core busi distribut servic larg driven drug
price drug mix gener versu brand drug overal
volum deceler pharmaceut drug growth due
slower brand drug inflat shift mix favor gener
drug lower price slower introduct blockbust drug
increas provid negoti leverag oper margin
pressur high cost specialti
pharmaceut drug off-set declin stem
introduct fewer brand drug overal oper
margin rel displac brand drug like lower
tout highest concentr among
competitor specialti drug repres roughli overal
revenu like help compani grow slightli faster
competitor recent similar two largest
distributor compani grown signific size
regular acquisit like necessari supplement growth
off-set overal market deceler slower growth
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
lead global third-parti logist provid
engag wholesal pharmaceut sourc distribut specialti
brand-nam gener pharmaceut relat servic
acute-car hospit health system independ chain retail
pharmaci mail order pharmaci medic clinic long-term care
altern site pharmaci physician practic dialysi clinic
healthcar custom acquir smaller compani manag
attain abil compound steril prepar distribut veterinari
pharmaceut vaccin transport biopharmaceut provid
inventori reimburs consult servic provid
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
month suspens wall street journal report
settlement involv payment billion three
major pharmaceut distributor time
period although term defend particip
appear fluid landmark settlement ahead
oct feder court kick surpris public
pharmaceut suppli compani want distanc
highli charg polit matter
remov largest overhang respect share
summar aug note decade-old
content pharmaceut suppli chain
culmin standoff ohio feder court
lawsuit repres state citi
counti accus drug manufactur activ market
addict drug pharmaceut distributor fail
detect/report suspici opioid order mani
defend case gener drug manufactur
pharmaceut distributor retail pharmaci
coverag drug manufactur spend signific dollar
market brand drug like crux civil
case unlik brand drug gener significantli
cheaper formul sold base price
activ market result think gener
manufactur face lower penalti settl
rel smaller amount brand opioid
indic previous believ settlement
would requir up-front payment dollar services/
product rather could spread multipl year
think make potenti settlement
manag compani coverag
factor smaller payment shorter time period
may modestli adjust fair valu estim revisit
sensit firm settlement figur releas
howev expect impact on-going oper
moat rate
rais fair valu estim amerisourcebergen
per share remov rebat rule
overhang impli fiscal ev/adjust ebitda
time free cash flow yield price-to-earnings
multipl
revenu driver price volum mix
disclos made sever assumpt project
industri growth except potenti extern
market shock anticip market share shift
dramat near term result anticip
overal annual top-lin growth roughli larg
benefit growth specialti pipelin
increas number therapi age popul
brand drug
compon growth varieti factor includ
neg slower growth introduct
new drug lesser extent gener
deflat
lower spend hepat
prescript opioid factor net anticip
industri revenu growth roughli
similar industri rang accord iqvia
expect revenu growth continu slow
declin histor compani growth high
singl digit histor revenu growth continu
lumpi due mix drug introduct inflat
gener albeit less industri roughli
howev lower gener price point would translat
roughli half overal pharmaceut distribut revenu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
growth overal revenu project
grow basi point higher base scenario
drive net growth slightli anticip industri
project scenario oper margin
anticip improv basi point due increas
revenu higher averag profit
bear-cas fair estim per share scenario
inflat increas volum slightli offset
price deflat lower growth anticip decreas
oper margin basi point signific
legisl regulatori chang extern shock
increas uncertainti downsid
uncertainti rate pharmaceut
distributor stand medium due competit
environ potenti extern shock includ
legisl chang increas price transpar
potenti entranc new competitor
attribut cost advantag
effect oper oligopoli
entrench within custom base
largest pharmaceut distributor global contract
manufactur capabl vertic integr
provid retail pharmaci chain canada
europ closest pure-play
pharmaceut distributor platform base insid
close provid retail pharmaci cardin
smallest three private-label
commod manufactur capabl medic devic
compani invest infrastructur provid
last three four year oper margin
industri declin oper margin
declin
fiscal model oper
margin declin fiscal
next five year
part valuat framework addit
base-cas dcf also model bull bear case
valuat scenario critic debat
surround compani abil entrench exist
partnership manufactur
negoti provid
financ
inventori manag servic
provid negoti provid specialti drug distribut
base current high level custom concentr
increas competit environ potenti
regulatori chang believ limit upsid
base scenario per share
bull-cas fair valu estim per share
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
abil navig highli regul drug market scale
also enabl compani negoti behalf
provid retail pharmaci requir infrastructur
regulatori hurdl requir logist manag
insul new entrant
cardin health
repres market role pharmaceut
distributor evolv increas number new
therapi format govern regulatori organ
regulatori requir licensur manufactur
retail pharmaci pharmaceut distributor
evolut compani continu invest
physic infrastructur provid logist
support effici compani scale also provid
abil negoti lower price drug manufactur
across comprehens portfolio gener brand
specialti drug behalf provid acut hospit
clinic mail pharmaci retail pharmaci
financ function provid manufactur
support commerci manufactur invest
autom infrastructur escal past
decad invest nearli
billion capit expenditur billion
acquisit billion strengthen foothold
merger amerisourc health bergen brunswig
slightli differ geographi creat larger entiti
stronger nation presenc sinc initi merger
compani made dozen acquisit rang
contract packag courier servic temperature-control
item world courier group home infus igg america
lead anim pharmaceut vaccin distributor
mwi veterinari suppli addit sever smaller
focus pharmaceut
distribut acquisit provid increment
revenu channel limit growth potenti
special natur success
acquisit around specialti account
increas percentag overal volum due rapid
acceler new specialti drug
manufactur product
commod natur servic reflect low
oper margin despit low margin compani
enjoy return invest capit larg
due scale growth driven strong drug inflat
pharmaceut revenu declin slower
inflat shift revenu mix margin like
declin increas negoti leverag
custom rise healthcar consolid
amerisourc top custom repres
revenu oper margin declin exacerb
rise govern scrutini acquir busi
drug compound factor weigh roic
despit near-term improv trend like
persist
current lack price transpar signific
variat list invoic price day-to-day
price volatil regulatori complianc recal
provid retail pharmaci
infrastructur quickli manag avail inform
negoti competit price manufactur
amerisourc volum also provid abil negoti
lower price drug manufactur increment scale
abil provid assist
inventori manag complianc financ
convers compani also support commerci
new drug deliveri product manufactur
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
signific declin pharmaceut market
growth caus distributor seek altern
channel acquisit entri new
area outsid core compet prove costli
compound busi acquir pharmedium sinc
regulatori scrutini compound increas
compani close largest site earli
continu expand new area
remain relev off-set declin core busi
execut regulatori risk increas concern
addit extern shock highli contest
reduct rebat increas price transpar
would diminish pharmaceut distributor
valu negoti transpar price
provid manufactur would less like need middl
man negoti rate would give custom
leverag renegoti distribut contract
amazon may immedi threat next sever
year discount altogeth
signific resourc appear method
gather expertis compet healthcar distribut
amazon signific inventori manag expertis
quietli accumul core piec need
compet pharmaceut distributor includ
pillpack state distributor licens joint
ventur jpmorgan berkshir hathaway
secur moat due scale
uncertain drug price environ grow
custom leverag limit narrow recent
howev pharmaceut revenu declin
slower inflat shift revenu mix increas
gener versu brand drug meanwhil margin
declin like due part increas negoti
leverag custom driven healthcar provid
consolid think oper margin pressur
like persist
trend rate despit insul provid
compani amass physic infrastructur
complex regulatori environ overal market
pressur continu build larg due declin
reimburs healthcar consolid declin
pressur manufactur provid press focu
contain cost result pharmaceut
distribut client activ solicit bid negoti
better price commod servic distributor
also includ client gener sourc joint ventur red
oak sourc cardin
walgreen claruson wal-mart
healthcar consolid also
increas concentr pharmaceut distribut
custom top custom
repres revenu market pressur
leverag pharmaceut distributor
custom
largest contributor
deterior overal industri margin
declin consecut last three four year even
manufactur appear test altern
direct shipment matur drug may limit
could also neg factor
like
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
key drug distributor handl
third pharmaceut distribut market
compani infrastructur provid scale abil
effect negoti price provid
inventori
oth compani servic enabl provid
manufactur focu core busi
outsourc logist drug highli
requir high sunk cost low oper margin
provid barrier entri highli matur
rivalri
declin reimburs matur market could
limit growth pressur profit
compani continu make acquisit
outsid core compet seek altern
channel growth execut regulatori risk
oextern shock legisl action increas
drug price transpar entranc
competitor could disrupt current oligopoli
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
believ enjoy posit solid
financi strength aris strong balanc sheet
posit matur market fiscal
billion cash
equival off-set billion debt result net debt
billion debt/capit ratio fiscal gross
leverag time adjust ebitda million senior
note outstand due view
challeng compani free cash flow gener
billion fiscal
lead pharmaceut distributor amerisourcebergen
disciplin acquisit dividend strategi
compani regularli complet acquisit increas
cross-sel opportun exist custom fuel
growth manag spent roughli billion
averag acquisit last four fiscal year
acceler histor trend annual common
stock dividend averag million last
year acceler million fiscal
dividend yield two peer
repurchas nearli billion worth
stock fiscal fiscal million
buyback fiscal manag roughli
million remain share repurchas author
believ compani continu repurchas share
exist author beyond
oper matur oligopoli
loss larg custom high custom concentr
regulatori chang entri new competitor
signific resourc overal market dynam could
reduc abil negoti drug manufactur
custom continu pressur drug price pose
risk compani includ deflat gener drug
price increas gener mix slower growth
pharmaceut pipelin lower spend hepat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
 opioid risk could eman propos
govern rule seek increas transpar drug
price elimin rebat pbm propos
regulatori chang would reduc cost drug
current pass-through revenu basi
pharmaci wholesal compens although
pharmaci distributor would opportun
negoti drugmak provid
uncertainti abil negoti industri
rate paid current increas transpar
continu consolid retail pharmaci could affect
compani abil negoti lower price
cornerston servic although threat new
competitor immin amazon compani
signific inventori manag expertis
quietli accumul core piec need compet
pharmaceut distributor
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
board director
stewardship rate overal leader season
divers background pharmaceut distribut
see govern issu
steven colli chairman presid chief execut
offic join compani specialti
pharmaci distribut segment signific
contributor key area growth compani
colli accumul year
experi pharmaci distribut
jame cleari jr execut vice presid chief
financi offic core member mwi veterinari
suppli compani acquir
sinc acquisit increas
respons execut vice presid group
presid global commerci servic
anim health segment current role cfo
robert mauch execut vice presid group presid
pharmaceut distribut strateg global sourc
join compani acquisit xcenda
founder year healthcar
experi sinc acquisit assist improv
custom experi compani oper chief
oper offic execut vice presid
presid
repres date owner name posit common share held report holder issuer
new york mellon corp
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
wide moat veeva announc plan acquir crossix
solut million includ million cash
million employe equiti grant acquisit
provid compani target market insight
optim experi commerci cloud nitro
user increment servic entrench veeva
exist life scienc custom increas
compani potenti wallet share underserv life
scienc market fair valu estim remain
unchang revisit increment transact
detail share
decreas blockbust primari care drug
rapid rise target specialti pharmaceut
patient popul increas payor involv
patient data analyt critic effici manag
limit resourc highli competit market crossix
current leverag collect patient data provid
market insight larg life scienc firm
complement veeva exist transact manag
tool roughli half drug approv fda
orphan drug industri estim indic
specialti pharmaci drug account roughli half overal
drug spend continu fuel overal growth specialti
drug continu grow effici demand
need address long-term goal improv overal
patient health lower cost
instanc largest pharmaci distributor made
igg america vantag oncolog
rxcrossroad covermym
intrafus insight provid acquisit allow
distributor stay relev evolv market
opioid litig overhang continu exert pain
drug manufactur distributor aug
across thousand civil case mostli
state court repres state prosecutor
compens famili hurt opioid
epidem plaintiff case accus drug
manufactur activ market addict drug
pharmaceut distributor fail detect/report
suspici opioid order mani defend
case gener drug manufactur pharmaceut
distributor retail pharmaci coverag
three pharmaceut distributor coverag
handl roughli drug dispens across
countri sophist infrastructur allow
track manag suppli logist drug
result key role distributor track drug
provid copi drug order drug enforc
administr histor role requir
polic opioid civil suit distributor
accus market profit distribut
opioid prosecut team alleg distributor
alert suspici spike opioid
volum step requir report
walgreen includ group compani
gener sourc joint ventur quarter
equiti stake
consider specul distributor activ
discuss prosecutor propos financi
settlement rang billion
distributor distributor like abl absorb
propos fine long spread multipl
first opioid case settl purdu
agre justic depart fine million
intens market push brand opioid drug
oxycontin subsequ purdu also settl
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
state washington charg over-
prescript oxycontin year
least eight state feder opioid settlement
defend agre pay larg fine
million
purdu million case settl aggreg
nearli billion span
recent financi demand acceler
fuel polit social activist advoc
compani compens famili impact opioid
crisi recent civil case settlement sum
loom billion local oklahoma court
purdu teva reach court settlement
million million respect aug
oklahoma judg rule johnson johnson fine
million compani plan appeal feder
court result abus discret local
oklahoma judg elect offici understand
purdu teva settl court avoid
potenti neg sway onto significantli larger feder
case pend ohio hit hardest addit
oklahoma case two gener drug manufactur
defens endo allergan settl ohio million
million respect reckitt benckis also agre
settl govern billion
oct consider leak propos term
suggest activ settlement negoti
play continu exert signific pressur relev
healthcar stock like impetu settl
consolid case eerili similar landmark
multi district litig mdl creat
relat civil person injuri wrong
death case asbesto manufactur notabl john
manvil mdl case tri en mass behalf
plaintiff similarli situat feder level
due larg number parti involv civil trial
schedul occur multipl track overal
defend anticip feder court neutral
venu rel local court run judg
special interest collect largest fine
drug manufactur distributor improv re-elect
aspir although activ negoti ohio behind
close door unidentifi sourc indic
purdu may explor unpreced
billion settlement decept market well-
known opioid painkil oxycontin purdu case
front center activ market brand opioid
aggreg revenu billion
asbesto mdl defend file bankruptci
protect strategi purdu may may
billion cumul settlement
settl decid opioid case financi
crippl defend includ legal fee
mount defens instanc estim
unlik prior civil case feder court ohio
propos consolid roughli civil case
across multipl district approxim
opioid case countri trial schedul kick
mani defend opioid litig
attent event transpir ohio prepar
respect defens base figur present
drug enforc administr purdu pharma
manufactur opioid pill
unlik larger peer compani activ market
brand drug teva manufactur opioid
pill distribut throughout countri time
period actavi pharma compani teva acquir
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
manufactur opioid pill distribut
time frame although opioid pill count
purdu rel lower manufactur
list prosecut appear aggress target
purdu opioid drug brand heavili
market drug manufactur spend signific dollar
market brand drug like crux civil
case unlik brand drug gener significantli
cheaper formul sold base price
activ market result case gener
manufactur produc larger quantiti
like penal heavili peer brand
opioid view
second largest distributor
grow faster peer indic
distributor fourth largest
volum opioid prescript period
billion pill amerisourc distribut partner
walgreen estim second largest opioid
distributor billion pill amerisourc growth
larg driven larger exposur specialti drug
improv sell-through servic walgreen
amerisourcebergen oper hinder
remedi cost compound busi acquir
continu success specialti like
mask drag next five year forecast
cash flow billion
cardin health smallest distributor growth
driven increas specialti mix compani
hinder integr prior acquisit especi
contract manufactur commod medic devic
indic distributor
third largest volum opioid pill billion
model free cash flow billion next sever
year aug compani file prospectu
sec unidentifi mix shelf offer common
prefer debt secur suspect file
pre-empt need fund propos opioid litig
largest distributor continu
challeng canada segment result
anticip compani grow slightli slower
peer compani least leverag forecast
gener largest free cash flow next five year
billion indic
distributor largest volum opioid pill billion
anim health specialti carri quarter
amerisourc scale remain distribut aug
result predominantli driven growth anim
health specialti drug despit mix shift toward
margin remain flat year year margin stabil
like attribut packag servic
healthcar provid leverag distributor scale
upsid
manag rais guidanc midpoint
total revenu anticip grow
midsingl digit anim servic consult
mid-single-digit area regular share
repurchas combin oper effici
provid boost earn growth share finish day
roughli seem appropri light
earn upsid note share sinc
end april but high
better-than-expect perform
elimin rebat rule overhang increas
fair valu estim
follow mix quarter
chang think may
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
report quarterli result
mix lighter-than-expect revenu better-than-
expect cost control although discret disclos
manag indic gener brand price
stabil anticip level impli volum
like softer expect strong cost control
time expens carri day drove ep upsid
rel expect despit quarterli ep
upsid manag inch full-year guidanc
one third ep benefit quarter share
roughli intra-day seem appropri light
earn upsid signific discount
high result reinforc belief scale
matter healthcar distribut therefor
maintain narrow moat rate per share fair valu
revenu expect grow midsingl digit despit
upsid quarterli ep guidanc increas
midpoint prior
guidanc suspect
conserv outlook reflect uncertainti around
time expens brand gener price mix
perform pharmedium
compound
fiscal second quarter revenu grew year
year billion normal ep increas year
year pharmaceut distribut revenu
increas driven increas volum double-
digit growth specialti drug growth walgreen boot
allianc stabil gener brand price
oper margin increas unchang
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end septemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
